MREO — Mereo BioPharma Cashflow Statement
0.000.00%
- $438.84m
- $376.36m
Annual cashflow statement for Mereo BioPharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | 20-F | 20-F | 10-K | 10-K |
Standards: | IFRS | IFRS | IFRS | USG | USG |
Status: | fx Final | fx Final | fx Final | Final | Final |
Net Income/Starting Line | -213 | 19.6 | -44.5 | — | — |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 166 | -29 | -4.62 | 8.87 | 9.7 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 9.01 | 1.35 | 0.36 | -31.1 | -43.6 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -36.3 | -7.2 | -47.8 | -21.1 | -32.8 |
Capital Expenditures | -0.021 | -0.736 | -0.012 | -0.419 | -0.699 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 1.94 | 0.157 | 1.86 | 0 | — |
Acquisition of Business | |||||
Sale of Business | |||||
Sale/Maturity of Investment | |||||
Sale of Intangible Assets | |||||
Change in Net Intangibles | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 1.92 | -0.579 | 1.84 | -0.419 | -0.699 |
Financing Cash Flow Items | -10.1 | -0.322 | 0.188 | -0.444 | -0.853 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 44.5 | 107 | -0.966 | 7.97 | 46.1 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 9.13 | 97.4 | -46.8 | -10.8 | 12.4 |